FINWIRES · TerminalLIVE
FINWIRES

$SYK

12 stories mentioning SYK

Every FINWIRES story that references SYK, newest first.

Insider Trading

Stryker Insider Sold Shares Worth $1,394,409, According to a Recent SEC Filing

Robert S Fletcher, Vice President, Chief Legal Officer, on May 28, 2026, sold 4,544 shares in Stryker (SYK) for $1,394,409. Following the Form 4 filing with the SEC, Fletcher has control over a total of 10,765 common shares of the company, with 10,582 shares held directly and 183 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/310764/000177507526000004/xslF345X05/wk-form4_1780088356.xml

$SYK
Insider Trading

Stryker Insider Sold Shares Worth $96,792,669, According to a Recent SEC Filing

Ronda E Stryker, Director, on May 26, 2026, sold 310,000 shares in Stryker (SYK) for $96,792,669. Following the Form 4 filing with the SEC, Stryker has control over a total of 14,817,258 common shares of the company, with 1,322 shares held directly and 14,815,936 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/310764/000124291426000008/xslF345X05/wk-form4_1780003353.xml

$SYK
Research

Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.

$SYK
Wire

JPMorgan Adjusts Stryker Price Target to $400 From $445, Maintains Overweight Rating

Stryker (SYK) has an average rating of overweight and mean price target of $402.04, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $306.88, Change: $-8.25, Percent Change: -2.62%

$SYK
Wire

Raymond James Adjusts Stryker Price Target to $383 From $418, Maintains Outperform Rating

Stryker (SYK) has an average rating of overweight and mean price target of $402.04, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $309.53, Change: $-5.61, Percent Change: -1.78%

$SYK
Wire

TD Cowen Adjusts Stryker Price Target to $355 From $387, Maintains Hold Rating

Stryker (SYK) has an average rating of overweight and mean price target of $402.04, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $309.28, Change: $-5.86, Percent Change: -1.86%

$SYK
Wire

Stifel Nicolaus Adjusts Stryker Price Target to $360 From $440, Maintains Buy Rating

Stryker (SYK) has an average rating of overweight and mean price target of $402.04, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $309.28, Change: $-5.86, Percent Change: -1.86%

$SYK
Wire

Goldman Sachs Adjusts Stryker Price Target to $361 From $357, Maintains Neutral Rating

Stryker (SYK) has an average rating of overweight and mean price target of $402.04, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $309.28, Change: $-5.86, Percent Change: -1.86%

$SYK
Research

Research Alert: Syk Q1 Miss Estimates, Announces Strategic Reorganization

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Stryker delivered a challenging Q1 2026 with adjusted EPS of $2.60 missing consensus by $0.38 and declining 8.5% from Q1 2025. Net sales reached $6.0B (+2.6% Y/Y) with 2.4% organic growth but missed expectations by $330M, impacted by a cybersecurity incident. We think the March 11 cybersecurity incident materially disrupted operations across segments, contributing to margin compression of 180 bps to 21.1% and $118M in incident-related costs. Management maintained full-year 2026 guidance of 8.0%-9.5% organic growth and $14.90-$15.10 EPS despite Q1 shortfall, signaling confidence in operational recovery. We see the strategic restructuring creating the new Ortho Tech business as positive, combining orthopaedic instruments with Mako technologies to simplify customer experience. The guidance implies significant acceleration in remaining quarters, though we expect continued near-term headwinds from operational disruptions and margin pressure.

$SYK
Wire

GUIDANCE: (SYK) Stryker Expects 2026 Adjusted EPS Range $14.90-$15.10, vs. FactSet Est of $13.99

GUIDANCE: (SYK) Stryker Expects 2026 Adjusted EPS Range $14.90-$15.10, vs. FactSet Est of $13.99

$SYK
Wire

Stryker's Fundamentals 'Solidly Intact' Despite Cyber Disruption, RBC Says

Stryker's (SYK) fundamentals remain solidly intact despite a recent cybersecurity disruption that could limit upside to the company's 2026 guidance, RBC Capital Markets said in a note Tuesday.Citing comments made by Stryker's competitor, Zimmer Biomet (ZBH), on its earnings call Tuesday, the brokerage said the cyber incident in Q1 did not appear to have translated into any meaningful share loss for Stryker.Zimmer executives said they did not materially benefit from Stryker's operational difficulties due to the cyber incident, while highlighting positive end-market dynamics, with no macro disruption, according to the note.The firm said a healthy orthopedic market with stable demand, steady pricing, reconstruction market growth above 4% and solid hospital capital spending on technology platforms provide a "favorable backdrop" for Stryker, which has resumed full operations following the cyber incident.Stryker has indicated the disruption is "not reasonably likely" to have a material effect on its 2026 outlook, which calls for organic revenue growth of 8% to 9.5%, the firm said.RBC Capital Markets reiterated an outperform rating on Stryker, with a price target of $435.Shares of Stryker were down about 2% in Wednesday trading.Price: $314.80, Change: $-6.63, Percent Change: -2.06%

$SYK$ZBH
Wire

Stryker's Q1 Results to See Material Impact From March Cybersecurity Incident, RBC Says

Stryker (SYK) is expected to see a financial impact to its Q1 results, when the company reports its quarterly results on May 1, owing to a cybersecurity incident that had a material impact on its operations, RBC Capital Markets said in a research note.RBC lowered its Q1 estimates on the company, expecting adjusted diluted earnings per share of $2.86 and revenue of $6.23 billion, and said on Monday that the cyberattack appears to have primarily disrupted Stryker's internal business systems rather than its product portfolio.RBC said it was encouraged with the company's belief that the cyberattack will probably not have a material impact on the company's 2026 guidance of 8% to 9.5% organic revenue growth, but added that any upside potential to this outlook is now "likely limited," and it remains unclear if lost sales will return later in the year.The bank maintained its outperform rating on Stryker with a $435 price target and said that it continues to see the company as "among the highest-quality, defensive names in its MedTech coverage delivering durable growth."Price: $351.43, Change: $+4.19, Percent Change: +1.21%

$SYK